Company: SWKH
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001628280-25-050155
Chunk: 16

Company: SWK Holdings Corp
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 1
Chunk 16
---
390 Cash flows from financing activities:Net settlement for employee taxes on stock options(89)(43)Net payments on credit facility(6,233)(12,350)Cash dividends(49,078)— Payments of financing costs(41)(50)Repurchases of common stock, including fees and expenses(3,067)(5,165)Net cash used in financing activities(58,508)(17,608)Net increase in cash and cash equivalents4,279 11,942 Cash and cash equivalents at beginning of period5,927 5,236 Cash and cash equivalents at end of period$10,206 $17,178 Supplemental non-cash investing and financing activities:Fair value of warrants received with finance receivables$— $1,073 Cash paid for interest$2,259 $2,403 Derecognition of right-of-use assets and operating lease liabilities upon termination of lease$— $82 

See accompanying notes to the unaudited condensed consolidated financial statements.

6

SWK HOLDINGS CORPORATION

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Note 1. SWK Holdings Corporation and Summary of Significant Accounting Policies

Nature of Operations SWK Holdings Corporation (the “Company,” “we,” or “us”) was incorporated in July 1996 in California and reincorporated in Delaware in September 1999. In July 2012, we commenced a strategy of building a specialty finance and asset management business. In August 2019, we commenced a complementary strategy of building a pharmaceutical development, manufacturing and intellectual property licensing business. Our operations were comprise of two reportable segments: “Finance Receivables” and “Pharmaceutical Development.” As a result of the sale of substantially all assets of the Pharmaceutical Development segment, the Finance Receivables segment will be the only remaining operating segment as of September 30, 2025. We evaluate and invest in a broad range of healthcare related companies and products with innovative intellectual property, including the biotechnology, medical device, medical diagnostics and related tools, animal health and pharmaceutical industries (collectively, “life sciences”). We allocate capital within our finance receivables portfolio in order to generate income through the sales of life science products by third parties and related earned income sources. The Company is headquartered in Dallas, Texas, and as of September 30, 2025, the Company had 9 full-time employees.The Company has